

Fusion Antibodies partners with Eurofins Discovery for preclinical drug discovery research

25 August 2021 | News

Fusion Antibodies will provide comprehensive pre-clinical antibody development services from discovery, engineering, and critical reagent supply to Eurofins



Fusion Antibodies, a specialist in pre-clinical antibody discovery, engineering, and supply for both therapeutic drug and diagnostic applications, has entered into a commercial collaboration with Eurofins, a Eurofins Scientific SE group company; a leading provider of products and services to the drug discovery industry.

The collaboration between Fusion Antibodies and Eurofins Discovery will last for an initial two-year period and is a commitment to provide world-class scientific expertise, next-generation technology, and guidance to accelerate the delivery of the best possible antibody against a broad range of targets and therapeutic areas into the clinic.

Under the agreement, Fusion Antibodies will provide comprehensive pre-clinical antibody development services from discovery, engineering, and critical reagent supply to Eurofins so that together they can provide a complete workflow solution for busy researchers. This includes Fusion Antibodies services for antibody generation, characterisation, sequencing, engineering and expression, and Eurofins Discovery's *in vivo* and *in vitro* services, such as efficacy models, bioanalytical services, biomarker development, phenotypic assays and safety assessment.

Commenting on the partnership, Dr Richard Jones, CEO, Fusion Antibodies, said, "This partnership is a natural fit with Fusion's mission to enable pharmaceutical and diagnostic companies to develop innovative products in the most efficient and cost-effective way."

Dr Julie Gormley, Business Development Director of Fusion Antibodies, said: "This partnership brings together two world leaders in their respective fields and will enable scientists to focus on their research while our services ensure efficient and robust results. I look forward to working closely with colleagues at Eurofins Discovery throughout 2021 and beyond."